Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Net Income (2016 - 2025)

Historic Net Income for Collegium Pharmaceutical (COLL) over the last 10 years, with Q3 2025 value amounting to $31.5 million.

  • Collegium Pharmaceutical's Net Income rose 23751.47% to $31.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.4 million, marking a year-over-year decrease of 3403.28%. This contributed to the annual value of $42.4 million for FY2024, which is 788.23% down from last year.
  • Collegium Pharmaceutical's Net Income amounted to $31.5 million in Q3 2025, which was up 23751.47% from $12.0 million recorded in Q2 2025.
  • In the past 5 years, Collegium Pharmaceutical's Net Income registered a high of $72.8 million during Q2 2021, and its lowest value of -$25.0 million during Q4 2021.
  • Over the past 5 years, Collegium Pharmaceutical's median Net Income value was $12.0 million (recorded in 2025), while the average stood at $11.0 million.
  • Over the last 5 years, Collegium Pharmaceutical's Net Income had its largest YoY gain of 757745.1% in 2021, and its largest YoY loss of 45978.73% in 2021.
  • Collegium Pharmaceutical's Net Income (Quarter) stood at -$25.0 million in 2021, then surged by 71.24% to -$7.2 million in 2022, then soared by 543.67% to $31.9 million in 2023, then plummeted by 60.75% to $12.5 million in 2024, then skyrocketed by 151.33% to $31.5 million in 2025.
  • Its last three reported values are $31.5 million in Q3 2025, $12.0 million for Q2 2025, and $2.4 million during Q1 2025.